Myelodysplastic-Myeloproliferative Diseases
"Myelodysplastic-Myeloproliferative Diseases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.
| Descriptor ID |
D054437
|
| MeSH Number(s) |
C15.378.190.615
|
| Concept/Terms |
Myelodysplastic-Myeloproliferative Diseases- Myelodysplastic-Myeloproliferative Diseases
- Disease, Myelodysplastic-Myeloproliferative
- Diseases, Myelodysplastic-Myeloproliferative
- Myelodysplastic Myeloproliferative Diseases
- Myelodysplastic-Myeloproliferative Disease
- Myeloproliferative-Myelodisplastic Diseases
- Disease, Myeloproliferative-Myelodisplastic
- Diseases, Myeloproliferative-Myelodisplastic
- Myeloproliferative Myelodisplastic Diseases
- Myeloproliferative-Myelodisplastic Disease
|
Below are MeSH descriptors whose meaning is more general than "Myelodysplastic-Myeloproliferative Diseases".
Below are MeSH descriptors whose meaning is more specific than "Myelodysplastic-Myeloproliferative Diseases".
This graph shows the total number of publications written about "Myelodysplastic-Myeloproliferative Diseases" by people in this website by year, and whether "Myelodysplastic-Myeloproliferative Diseases" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Myelodysplastic-Myeloproliferative Diseases" by people in Profiles.
-
Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies. Mod Pathol. 2023 06; 36(6):100166.
-
Advances in myelodysplastic/myeloproliferative neoplasms. Virchows Arch. 2023 Jan; 482(1):69-83.
-
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia. 2022 12; 36(12):2934-2938.
-
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia. 2022 05; 36(5):1432-1435.
-
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2022 01; 63(1):199-204.
-
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.
-
Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Mod Pathol. 2021 01; 34(1):20-31.
-
Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2020 04; 61(4):963-966.
-
Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Leuk Lymphoma. 2019 12; 60(12):2993-3001.
-
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019 03 26; 3(6):922-933.